Scholar Rock Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Scholar Rock Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11322
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Scholar Rock Inc (Scholar Rock), a subsidiary of Scholar Rock Holding Corp, is a biopharmaceutical company that discovers and develops novel medicines for serious unmet medical needs. Its proprietary technology platform develops new medicines, modulating supracellular activation, for the application in the treatment of fibrosis, diseases of musculoskeletal systems, and autoimmune diseases. Scholar Rock’s lead product candidate include SRK-015, a selective inhibitor which activates latent myostatin in skeletal muscle used for the treatment of spinal muscular atrophy (SMA). The company is creating a pipeline of novel product candidates for a wide range of serious diseases such as neuromuscular disorders, cancer, fibrosis, and anemia. It collaborates with various biotechnology companies for the development of its pipeline products. Scholar Rock is headquartered in Cambridge, Massachusetts, the US.

Scholar Rock Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Scholar Rock Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Scholar Rock Raises USD47 Million in Series C Financing 10
Scholar Rock Raises USD36 Million in Series B Financing 12
Scholar Rock Raises USD20 Million in Series A Venture Financing 14
Partnerships 16
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 16
Licensing Agreements 17
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 17
Scholar Rock Enters into Licensing Agreement with Boston Children’s Hospital 18
Scholar Rock Inc – Key Competitors 19
Scholar Rock Inc – Key Employees 20
Scholar Rock Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Aug 08, 2018: Scholar Rock reports second quarter 2018 financial results and updates on business progress 22
Corporate Communications 24
Apr 09, 2018: Scholar Rock Appoints Rhonda Chicko as Chief Financial Officer 24
Jul 06, 2017: Scholar Rock Appoints David L. Hallal as Chairman of Board of Directors 25
May 23, 2017: Scholar Rock Announces Drug Development Leaders, Michael Gilman and Shelia Violette, to Join Scientific Advisory Board 26
Product News 28
01/23/2018: Scholar Rock and Collaborators at Harvard Medical School and Northeastern University Elucidate Molecular Basis of Myostatin Activation – a Key Physiological Process in Muscle Health 28
Clinical Trials 29
Jul 10, 2017: Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium 29
Jun 28, 2017: Scholar Rock to Develop SRK-015 to Improve Muscle Function in Patients with Spinal Muscular Atrophy 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Scholar Rock Inc, Pharmaceuticals & Healthcare, Key Facts 2
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Scholar Rock Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Scholar Rock Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Scholar Rock Raises USD47 Million in Series C Financing 10
Scholar Rock Raises USD36 Million in Series B Financing 12
Scholar Rock Raises USD20 Million in Series A Venture Financing 14
Scholar Rock Enters Into Research Collaboration With Johnson & Johnson Innovation And Janssen Biotech 16
Janssen Biotech Exercises Option for Licensing Agreement with Scholar Rock 17
Scholar Rock Enters into Licensing Agreement with Boston Children's Hospital 18
Scholar Rock Inc, Key Competitors 19
Scholar Rock Inc, Key Employees 20

List of Figures
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Scholar Rock Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Scholar Rock Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Intelsat S.A. (I):企業の財務・戦略的SWOT分析
    Intelsat S.A. (I) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Hindustan ZInc Ltd:企業の戦略・SWOT・財務分析
    Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Medworxx Inc-医療機器分野:企業M&A・提携分析
    Summary Medworxx Inc (Medworxx), a subsidiary of Aptean Inc is an information technology solution provider that offers software solutions for patient flow, compliance, and education. The company’s software products include patient throughput review software, clinical criteria software, forms and ass …
  • Citibank NA:企業の戦略・SWOT・財務情報
    Citibank NA - Strategy, SWOT and Corporate Finance Report Summary Citibank NA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Suzuki Motor Corporation (7269):企業の財務・戦略的SWOT分析
    Suzuki Motor Corporation (7269) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Pancake House, Inc.:企業の戦略・SWOT・財務情報
    Pancake House, Inc. - Strategy, SWOT and Corporate Finance Report Summary Pancake House, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Latvenergo AS-エネルギー分野:企業M&A・提携分析
    Summary Latvenergo AS (Latvenergo) is a state-owned power supply utility company that generates and supplies electricity and thermal energy, distributes electricity, leases transmission system assets. It generates electricity through various renewable energy sources such as hydropower, biomass, wind …
  • Genmab AS (GMAB):企業の財務・戦略的SWOT分析
    Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • HNI Corp (HNI):企業の財務・戦略的SWOT分析
    HNI Corp (HNI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Xtant Medical Holdings Inc (XTNT):医療機器:M&Aディール及び事業提携情報
    Summary Xtant Medical Holdings Inc (Xtant Medical), formerly Bacterin International Holdings Inc, is a medical device company that develops regenerative medicine products and medical devices. The company’s products include 3Demin, osteosponge, osteosponge SC, osteoselect DBM Putty, OsteoSTX, osteowr …
  • Brooks MacDonald Group PLC (BRK):企業の財務・戦略的SWOT分析
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Colabor Group Inc (GCL):企業の財務・戦略的SWOT分析
    Colabor Group Inc (GCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Otsuka Pharmaceutical Co Ltd-医療機器分野:企業M&A・提携分析
    Summary Otsuka Pharmaceutical Co Ltd (OPC), a subsidiary of Otsuka Holdings Co Ltd is a provider of healthcare products. The company offers products which include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, jarinea, five mini, amino-value, enerugen, jog mat …
  • Phase Holographic Imaging AB:医療機器:M&Aディール及び事業提携情報
    Summary Phase Holographic Imaging AB (PHI) is a medical device company that develops time-lapse cytometry instrumentation and software. The company’s products include HoloMonitor M4 and demo software. Its HoloMonitor time-lapse cytometers provides cellular behavior to be continuously quantified and …
  • China Petroleum & Chemical Corporation (600028)-石油・ガス分野:企業M&A・提携分析
    Summary China Petroleum & Chemical Corporation (Sinopec), a subsidiary of China Petrochemical Corporation, is a vertically integrated energy and chemical company. It is involved in the oil and gas exploration and production, extraction, pipeline transmission and marketing; oil refining; and producti …
  • Yungjin Pharm Co Ltd (003520):製薬・医療:M&Aディール及び事業提携情報
    Summary Yungjin Pharm Co Ltd (Yungjin), a subsidiary of KT&G Corp is a pharmaceutical company that develops, manufactures and distributes active pharmaceutical ingredients, formulations and tonic drinks. The company provides API products such as cephalosporins and other general products. It also off …
  • Crystal Rock Holdings, Inc:企業の戦略・SWOT・財務情報
    Crystal Rock Holdings, Inc - Strategy, SWOT and Corporate Finance Report Summary Crystal Rock Holdings, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Dignity Health-製薬・医療分野:企業M&A・提携分析
    Summary Dignity Health is a healthcare service provider that offers patient care services. The center provides health care services that include allergy, behavioral health, anesthesiology, cardiology, chronic care, geriatrics, dermatology, emergency medicine, endocrinology, gastroenterology, immunol …
  • Hopewell Holdings Ltd (54):企業の財務・戦略的SWOT分析
    Hopewell Holdings Ltd (54) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆